Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

161-180 of 847 trials

Focal Segmental Glomerulosclerosis: DMX-200 Treatment Study

We are studying the effects of DMX-200 on kidney function in patients with focal segmental glomerulosclerosis who are taking an angiotensin II receptor blocker. This trial will help us understand its safety and effectiveness compared to standard treatments.

Focal Segmental Glomerulosclerosis>2 yearsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Partially RemoteNephrology

Chronic Lymphocytic Leukemia: Venetoclax and Obinutuzumab Study

We are assessing the effectiveness and safety of a combination treatment for adults with recurring chronic lymphocytic leukemia. This study aims to understand how well the treatment works and what side effects may occur.

Recurrent Chronic Lymphocytic Leukemia1-2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyOncology

Hepatocellular Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a combination of two medications for people with advanced liver cancer who have not had prior treatment. The goal is to find the best dose and assess safety and effectiveness.

Metastatic Liver Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteHepatologyOncology

Choroidal Melanoma: Belzupacap Sarotalocan Treatment

We are studying a new treatment for people with primary indeterminate lesions or small choroidal melanoma. The goal is to see if it is more effective and safe compared to a placebo.

Choroidal Melanoma>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementOncologyOphthalmology

Cholestatic Pruritus: Volixibat Study

We are testing a new drug, volixibat, for patients with itching caused by primary biliary cholangitis. The study aims to see if it can reduce itching and improve quality of life compared to a placebo.

Primary Biliary Cholangitis6-12 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHepatologyInternal Medicine

Anti-NMDA Receptor Encephalitis: Inebilizumab Study

We are testing a new treatment called inebilizumab for people with anti-NMDA receptor encephalitis. The study aims to see if it helps improve disability compared to a placebo.

Anti-NMDA Receptor Encephalitis1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Partially RemoteInternal MedicineNeurology

HER2-Expressing Tumors: Trastuzumab Deruxtecan Study

We are studying the safety and effectiveness of Trastuzumab Deruxtecan in patients with advanced HER2-expressing tumors. This research aims to provide insights into new treatment possibilities for these patients.

HER2 Expressing Tumors6-12 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Myelofibrosis: Navtemadlin with Ruxolitinib

We are studying whether adding navtemadlin to ruxolitinib helps patients with myelofibrosis who aren't responding well to their current treatment. The trial looks at changes in spleen size and symptoms, along with safety and survival.

MyelofibrosisPrimary MyelofibrosisSecondary Myelofibrosis>2 yearsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost ReimbursementHematologyOncology

Cushing’s Disease: Lu AG13909 Treatment Study

We are investigating a new medication, Lu AG13909, for adults with Cushing’s disease to see how it affects cortisol levels and its safety. This trial aims to improve understanding of this rare condition and its treatment options.

Cushing's Disease1-2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteEndocrinologyInternal Medicine

Guselkumab for Pediatric Crohn’s Disease

We are studying the safety and effectiveness of guselkumab in children with moderately to severely active Crohn’s disease. This trial aims to see how well the treatment works after initial positive responses.

Crohn's Disease1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Chronic Pouchitis in Children: Vedolizumab IV Study

We are testing the intravenous medication vedolizumab in children with active chronic pouchitis to see if it helps them achieve remission. The study will also look at how well the treatment is tolerated and its overall effectiveness.

Pouchitis1-2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyPediatrics

Epcoritamab for Relapsed/Refractory Chronic Lymphocytic Leukemia

We are studying a new treatment called epcoritamab for patients with relapsed or refractory chronic lymphocytic leukemia and Richter's syndrome. The goal is to assess its safety and effectiveness, both alone and with other medications.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncology

Advanced Solid Tumors: GRWD5769 Treatment Study

We are testing the safety and effectiveness of GRWD5769 alone and with cemiplimab in patients with advanced solid tumors. This study aims to find out how well these treatments work and their tolerability.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Sotatercept for Children with Pulmonary Artery Hypertension

We are studying the safety and effects of sotatercept in children aged 1 to under 18 with pulmonary artery hypertension. This research aims to improve treatment options for young patients already receiving standard care.

Pulmonary Arterial Hypertension3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteCardiologyPulmonology

Cutaneous Lupus Erythematosus: Litifilimab Injections

We are studying the long-term safety and effects of Litifilimab injections for adults with active cutaneous lupus erythematosus who have not responded to other treatments. This research aims to see if it can improve symptoms and overall quality of life.

Skin Lupus (Cutaneous Lupus Erythematosus)>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementDermatologyRheumatology

Bomedemstat vs Best Available Therapy for Essential Thrombocythemia

We are studying a new treatment for patients with essential thrombocythemia who haven't responded to hydroxyurea. The trial aims to see if bomedemstat is safer and more effective than current therapies.

Essential Thrombocythemia>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementHematology

Chronic Kidney Disease in Children: Finerenone Study

We are studying how well finerenone works and its safety for children with chronic kidney disease and proteinuria. This trial will help us understand its effects when used with standard treatments.

ProteinuriaChronic Kidney Disease6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNephrology

Chronic Kidney Disease: Finerenone Safety Study

We are studying the long-term safety of finerenone for children and young adults with chronic kidney disease. This trial looks at its effects when used alongside standard treatments like ACE inhibitors or ARBs.

Chronic Kidney DiseaseProteinuria1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteNephrologyPediatrics

Progressive Pulmonary Fibrosis: Inhaled Treprostinil Study

We are investigating whether inhaled treprostinil can improve lung function in people with progressive pulmonary fibrosis. The study will also assess its safety and impact on overall health.

Progressive Pulmonary Fibrosis1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access Standard MedicinesPulmonology

Advanced Breast Cancer: Capivasertib with CDK4/6 Inhibitors

We are studying a new treatment combining capivasertib with CDK4/6 inhibitors and fulvestrant for patients with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this combination improves treatment outcomes compared to standard therapies.

Hormone Receptor-Positive and HER2-Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Search Clinical Trials in the European Union